Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II Study of WT4869 in Patients with Myelodysplastic Syndromes
jRCT2080221337Phase 2Terminated
- Sponsor
- Sumitomo Pharma
- Start
- Dec 2010
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT4869 in myelodysplastic syndrome (MDS) and refractory anemia with excess blasts in transformation (RAEB-T), sponsored by Sumitomo Pharma. Started Dec 2010; status: terminated.
02
Drugs
WT4869
03
Conditions
myelodysplastic syndrome (MDS)refractory anemia with excess blasts in transformation (RAEB-T)
Beyond the preview
Go deeper on jRCT2080221337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221337.